Idarubicin (IDA) is an anthracycline anticancer drug utilized in the treatment of acute leukemias. There are conflicting data published with regard to the cross-resistance of IDA in multidrug-resistant (MDR) cells expressing P-glycoprotein (P-gp). We evaluated the cytotoxicity and cellular accumulation of IDA in a panel of anthracycline-selected MDR cell lines. Leukemia K562/R7 cells and sarcoma MES-SA/Dx5 cells expressing high levels of the MDR1 (ABCB1) gene were resistant to IDA (42-fold and 150-fold, respectively). In both of these cell lines, resistance to IDA was equivalent to that for doxorubicin, the drug used to select for the MDR variants. The P-gp inhibitor PSC 833 (valspodar) at 2 mM completely restored sensitivity to IDA. IDA accumulation was decreased 12-fold in MES-SA/ Dx5 cells vs parental cell line, and drug uptake was restored to control levels by PSC 833. Reduced intracellular IDA was correlated with P-gp content by flow cytometry. Experiments in NIH3T3 murine cells transfected with the human MDR1 gene substantiated the findings of cross-resistance to IDA and reversal of resistance by PSC 833. Our data indicate that IDA is a high-affinity substrate for P-gp.
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INTRODUCTION
The anthracyclines doxorubicin (DOX) and daunorubicin (DNR) are important antineoplastic agents, but their clinical effectiveness is limited by cardiotoxicity, myelosuppression, and cellular drug resistance. An important mechanism of cellular resistance to anthracyclines is multidrug resistance (MDR) as mediated by the MDR1 (ABCB1) gene. The MDR1 gene product P-glycoprotein (P-gp) is an ATP-dependent efflux pump for drugs such as the anthracyclines, Vinca alkaloids, taxanes, epipodophyllotoxins, and other compounds.
Idarubicin (IDA, Figure 1 ) is an anthracycline antibiotic which is more potent in vitro than DOX or DNR (1) (2) (3) (4) (5) . Similar to these agents, IDA intercalates DNA, induces DNA strand breaks, and inhibits topoisomerase II activity by forming a DNA-enzyme-drug ternary complex (1, 4) . Preclinical studies have shown that IDA is less cardiotoxic than DOX or DNR at doses producing the same hematological toxicity in several animal models (1, 6) .
IDA was introduced in 1990 for the treatment of acute myeloid leukemia (AML), a disease in which MDR1 has been implicated as an important mechanism of resistance to therapy (7, 8) . In patients with AML, MDR1 gene expression has been described to occur de novo and at an increased frequency in patients after relapse (7). There have been numerous studies using IDA in the treatment of acute leukemia, especially AML. In newly diagnosed patients with AML, studies using IDA in combination with cytarabine (ARA-C) suggest that it is equal to or better than regimens containing DNR (9) (10) (11) (12) .
The intracellular distribution of IDA differs from other anthracyclines, leading to the possibility that alternate targets may be responsible for the drug's cytotoxicity (13) . Michieli et al. (14) determined the sensitivity of several anthracycline derivatives in
human sarcoma and leukemia MDR cell lines. Their results indicated that P-gp expression was strongly associated with resistance to DOX and DNR, but not to IDA. In addition, this study found that IDA accumulated 10 times more than DNR in the vinblastine-selected human lymphoblastic leukemia cell line, CEM-VBL (14) . Several investigators have suggested that IDA is a poor P-gp substrate and perhaps this, in addition to its increased lipophilicity, enables the drug to overcome this form of MDR (14) (15) (16) (17) (18) (19) (20) . However, full restoration of sensitivity to IDA could be achieved in MDR1 variants by incorporating the known MDR modulators, such as verapamil (VER) and cyclosporine (21) .
Given the contradictory reports in the literature, we evaluated the cytotoxicity of IDA in the human MDR cell lines, leukemia K562/R7, and sarcoma MES-SA/Dx5, which express high levels of the MDR1 gene. We measured the intracellular drug accumulation in MES-SA/ Dx5 cells by detecting IDA fluorescence using interactive laser cytometry in the presence and absence of an inhibitor of P-gp, the cyclosporine PSC 833 (PSC, valspodar). IDA accumulation was confirmed by two-color flourescenceactivated cell sorter (FACS) analysis incorporating a UIC2-Texas Red label for P-gp content. In order to confirm specific cross-resistance to P-gp, we also studied the cytotoxicity of IDA and reversal of resistance by PSC in NIH3T3 cells transfected with the human MDR1 gene. Our results indicate that IDA is a P-gp substrate. The use of MDR modulators with IDA therapy may enhance its clinical efficacy as in the case of de novo or relapsed AML.
MATERIALS AND METHODS

Drugs
DOX was purchased as commercial preparation (Adria Laboratories, Columbus, OH). IDA was a gift from Farmitalia Carlo Erba (Milan, Italy). Novartis Pharmaceuticals (East Hanover, NJ) provided the cyclosporin D analogue PSC 833. All drugs were initially solubilized in 100% ethanol at a concentration of 1 mM, followed by subsequent dilutions with culture medium for cytotoxicity assays and drug accumulation studies. Stock solutions of all drugs were stored at À20 C.
Cell Culture MES-SA and K562 cells were selected for resistance to DOX using step-wise selection. The resulting sublines MES-SA/Dx5 and K562/R7 express high levels of MDR1 mRNA by reverse transcriptase-polymerase chain reaction (rt-PCR), as well as the gene product, P-glycoprotein (22, 23 Lacayo NJ et al.
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supplemented with 10% fetal calf serum (Invitrogen Life Technologies, Carlsbad, CA). All cell lines were grown in a humidified incubator maintained at 37 C and 5% CO 2 .
MTT Cytotoxicity Assay
The cytotoxicity of various drugs was determined using a modified MTT assay (24) . Briefly, cells in the logarithmic phase of growth were seeded into 96-well microtiter plates (Falcon, Becton Dickinson, Lincoln Park, NJ, U.S.A.) and allowed to settle/ attach overnight prior to drug treatment. The cells were then grown in various concentrations of drug for 72 h (approximately three cell divisions). 10% (v/v) of a 5-mg MTT/ml of PBS was then added to each well. After the plates were incubated for an additional 2-3 h at 37 C, 5% CO 2 , 100 l of 0.1N HCl-acidified isopropanol was added to each well to solubilize the formazan crystals. Absorbance at 570 nm was read on a UV-Thermomax multiwell spectrophotometer (Molecular Devices, Sunnyvale, CA). Each drug concentration was tested in quadruplicate measurements per experiment, and each experiment was carried out at least three times. Percent survival was calculated as the percent of absorbance of the treated wells relative to that of the untreated wells, and IC 50 values were calculated directly from semi-logarithmic growth curves.
Interactive Laser Cytometry Drug accumulation was determined by measuring intracellular fluorescence using an interactive laser cytometer. Approximately, 1.5Â10 5 cells were plated and allowed to attach to 35Â10-mm tissue culture dishes overnight. DOX or IDA was added to the medium of the culture dish at a final drug concentration of 1 M. The culture dishes were incubated for 1 h in a cell-culture incubator at 37 C. The medium was aspirated and each dish was rinsed twice with ice-cold PBS prior to the analysis. The dish was immediately scanned using an interactive laser cytometer equipped with an Olympus IMT-2 inverted microscope and an argon-ion laser as a light source, with a 80386 computer system for data processing and storage (ACAS 570, Meridian Instruments, Okemos, MI). Intracellular fluorescent emission was detected as pixels, which were digitalized by the computer to represent the relative intensity of the emission as fluorescence values. Each dish was scanned at an excitation wavelength of 488 nm for 180 steps, with each step width of 2 mm at a scanning speed of 20 mm s
À1
.
Flow Cytometry
Suspensions of cultured cells were passed through a nylon filter, centrifuged, and resuspended in phenol red-free Hank's Balanced Salt Solution (HBSS) containing 10 mM HEPES (all Invitrogen Life Technologies, Carlsbad, CA). Aliquots of 1 ml containing 2.5Â10 5 cells were incubated with PSC (2 M) at 37
C for 1 h. IDA was added to give a final concentration of 1M, followed by a 45-min incubation at 37 C. Cells were centrifuged and the pellet was resuspended in 1 ml HBSS, containing the same concentrations of PSC. Following a 20-min drug efflux at 37 C, cells were pelleted and resuspended in 200 l of cold HBSS (4 C). Double labeling with the monoclonal antibody UIC2 (Beckman Coulter, Fullerton, CA) was performed according to a previously described method (25, 26) . Following the 20-min efflux step, cells were stained with UIC2 (final concentration of 40 g/ml) or with a mouse immunoglobulin G2a (IgG2a) isotype control. After a 20-min incubation at 4 C, cells were centrifuged through a fetal calf serum cushion, then resuspended and incubated with a Texas Red-conjugated goat antimouse IgG2a secondary antibody (Caltag Laboratories, Burlingame, CA). Cells were centrifuged through a fetal calf serum cushion, the pellet was resuspended in 200 l of cold HBSS, and cells were kept at 4 C until analyzed at the Stanford FACS facility using a modified FACS II (Becton Dickinson, San Jose, CA).
RESULTS
IDA Sensitivity Patterns in Three MDR Models
A modified MTT assay was used to study the cytotoxicity of DOX and IDA with and Table 1 . The relative potency of IDA was greater than DOX in the K562 and MES-SA cell lines (eight-fold and 13-fold, respectively). In the P-gp-positive cells, the IC 50 values for DOX and IDA were significantly increased when compared to the parental controls. The DOX-selected MES-SA/Dx5 was 100-fold resistant to DOX relative to MES-SA, and K562/R7 was 48-fold resistant to DOX relative to K562. When exposed to IDA, MES-SA/Dx5 was 150-fold resistant to IDA, and K562/R7 was 42-fold resistant to IDA. Co-incubation with PSC at 2 M completely restored DOX and IDA sensitivity to wild-type levels in these MDR1 variants. These data indicate that the MDR models tested were equally resistant to IDA as to the selecting agent DOX and that the cell lines were sensitive to MDR modulation. In addition, the MDR1-transfected NIH3T3/Col 1000 was 15-fold resistant to DOX and eightfold resistant to IDA relative to the wild-type control. As in the other MDR models tested, co-incubation with 2-M PSC restored both OX and IDA sensitivity to NIH3T3 levels. These studies confirmed that MDR1 expression confers resistance to IDA to the same degree as for DOX, and that this resistance may be reversed by the known P-gp inhibitors.
Intracellular IDA Fluorescence in the Presence and Absence of P-gp Inhibitors as Measured by Laser Cytometry
Topographical plots from interactive laser cytometry reveal an altered IDA accumulation pattern in the MDR models tested from parental controls. There was a 12-fold decrease in IDA accumulation in MES-SA/Dx5 relative to MES-SA (Figures 2A-C and 3 ). This deficit was reversed upon the addition of the MDR modulator PSC at 2 M and returned to only a 1.7-fold decrease in the average intracellular fluorescence relative to MES-SA cells. Studies with the MDR1-transfected cell line NIH3T3/Col 1000 and the wild-type NIH3T3 cells confirmed these results ( Figures 2D-F and 3 ). Once again, we observed a 10-fold decrease in IDA accumulation in NIH3T3/Col 1000 cells relative to wild-type cells, and IDA levels were restored with PSC co-incubation. Similar results were obtained using VER as the MDR modulator (6-10 M, data not shown).
IDA Accumulation Correlated with P-gp Staining by FACS Analysis
Dual-labeling studies using the anti-P-gp monoclonal antibody UIC2 enabled correlation of P-gp content and function. These results are summarized in Figure 4 . The wild-type cell line MES-SA had equivalent 
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UIC2-Texas Red staining as the IgG2a isotype control and had high levels of intracellular IDA ( Figure 4A ). UIC2 staining confirmed the P-gp status of MES-SA/Dx5, and this same population accumulated 60-fold less IDA than MES-SA ( Figure 4C ). This P-gp-positive population shifted to MES-SA levels of intracellular IDA in the presence of the MDR modulators PSC ( Figure 4D ) or VER (data not shown). Co-incubation with modulators did not have a . Co-incubation with the P-glycoprotein (P-gp) inhibitor PSC at 2 mM restores IDA fluorescence to MES-SA levels (C). In order to confirm our results obtained in a doxorubicin-selected MDR1 variant, we repeated these experiments in the MDR1-transfected NIH3T3/Col 1000 cell line (D). The wild-type NIH 3T3 accumulation pattern is depicted. Quite like the MES-SA/Dx5 cells, the NIH3T3/Col 1000 cells efflux IDA due to P-gp expression (E), and co-incubation with 2-mM PSC restores IDA accumulation to control levels (F). Figure 4B ). These results verified the data obtained using the interactive laser cytometer and confirmed that the lower IDA accumulation resulted from P-gp-mediated drug efflux.
Colour figure
DISCUSSION
The results from our experiments are consistent with reports in the literature that suggest that IDA is indeed a P-gp substrate (21, 27, 28) . All of our MDR1-positive cell models were resistant to IDA and DOX, and this resistance was correlated with reduced IDA accumulation relative to parental controls as determined by measuring its natural fluorescence using a laser cytometer and FACS analysis. PSC at 2 M, a concentration previously shown to be sufficient to achieve MDR modulation in vitro (29) , was able to reverse the resistance in all of the MDR1-expressing cells in an MTT cell proliferation assay. In addition, PSC was able to restore IDA and DOX accumulation to wildtype levels. These observations were confirmed in a murine NIH3T3 cell line transfected with the full-length MDR1 gene. The dual-labeling FACS studies clearly identified that the reduced IDA accumulation was associated with P-gp expression and that IDA accumulation could be restored to wild-type levels in the presence of known MDR modulators. Collectively, our data suggest that IDA is a high-affinity substrate for P-gp and that MDR modulators can re-sensitize cells by competitively inhibiting P-gp.
Given the minor modifications in the chemical structure of IDA (see Figure 1) , we would not expect a major change in the drug's affinity for P-gp compared to DOX. Modifications in the sugar moiety appear to determine P-gp substrate specificity, as in the case of the morpholinyl anthracycline derivatives (30) . In the case of IDA, the sugar moiety is left intact, and our MDR cell models are equally resistant to IDA as they are to DOX.
There are several explanations for the contradictory reports found in the literature. First, Muller et al. (17) studied the reversal agent VER in relation to the expression of P-gp by a semi-quantitative flow-cytometric procedure in blast cells isolated from 37 patients with newly diagnosed and pretreated AML. No relationship was found between the in vitro sensitivity to IDA and P-gp content. VER at a concentration of 2 M sensitized cells to DOX and VCR significantly, but it was insufficient to modulate the cytotoxicity of IDA. The failure to modulate IDA resistance is likely to be due to the inadequate concentration of VER used in this study. In our experience, levels of up to 6-12-M VER are required for substantial modulation of MDR, and we were able to demonstrate the ability of 6-M VER to reverse resistance to IDA in our MDR models.
Second, Berman and McBride concluded that IDA uptake at an extracellular concentration of 10 M was identical in the MDR1 variants CEM-VBL and HL-60/AR compared to their respective controls (16) . However, the high concentration of IDA used in this study may have saturated the P-gp transporter and may have inhibited the action of P-gp, masking the underlying drug resistance. This high IDA drug concentration also may explain why VER had no incremental effect on the accumulation of IDA as measured by flow cytometry. In comparison, our results demonstrate that there is a significant decrease in IDA accumulation at 1 M due to efflux by P-gp. Berman and McBride also found that the combination of DNR and VER resulted in approximately 80% growth inhibition in clonogenic assays, whereas Lacayo NJ et al.
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treatment with IDA alone at the same concentration as DNR resulted in greater than 95% growth inhibition (16) . We interpret this to reflect the increased relative potency of IDA over DNR and DOX. In our experiments, IDA was clearly more potent than DOX with and without modulators in our MDR cell models, but full sensitization was only achieved in the presence of P-gp inhibitors.
As suggested by Toffoli et al. (13) , there appears to be a different intracellular distribution of IDA relative to DNR and DOX, and this may be partially responsible for IDA's enhanced potency. Several studies have found that the rate of uptake significantly exceeds the rate of efflux of IDA when compared to DNR, DOX, and the new anthracycline, annamycin (27, 28, 31, 32) , resulting in higher intracellular levels than other anthracyclines at equivalent extracellular concentrations. The increased potency due to this altered rate of drug retention does not imply that the drug can circumvent the action of P-gp. We have demonstrated that IDA can be transported by P-gp in our MDR models Figure 4 . Fluorescence-activated cell sorter analysis confirms the data obtained using the ACAS 570 laser cytometer. Intracellular idarubicin (IDA) fluorescence was detected at the same spectra as fluorescein, and cells were dual-labeled using the anti-P-glycoprotein (anti-P-gp) monoclonal antibody UIC2 recognized by a Texas Red-conjugated secondary antibody. The Texas Red measurement for MES-SA cells was equivalent to the negative control (mouse IgG2a control), and IDA fluorescence was high (A). Co-incubation with 2-mM PSC had no effect on IDA accumulation in MES-SA cells (B). The doxorubicin-selected MDR1 variant MES-SA/Dx5 was bright in the Texas Red channel (approximately 15-fold higher than MES-SA and the IgG2a control), confirming the P-gp status of this cell line (C). This same population is dull for IDA fluorescence as a result of this P-gp expression, and co-incubation with 2-mM PSC completely restored IDA uptake to control levels (D).
at clinically relevant drug concentrations and that resistance to IDA can be modulated using known P-gp inhibitors.
Most clinical trials in adults and children have demonstrated the enhanced potency of IDA over DNR in remission induction (33) (34) (35) (36) . Some studies have suggested that IDA efficacy is further improved in the presence of MDR modulators (37) (38) (39) (40) (41) . In view of the results from our study, further clinical trials are warranted that combine MDR modulators with IDA in less toxic regimens (42) . The design of these clinical trials should prospectively identify patients whose pretreatment cells show P-gp expression and function (42) , especially in pediatric trials where MDR1 expression is less frequent than in adult leukemias and where this mechanism has not been well established as a poor prognostic indicator (43) .
